| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Prime Medicine, Inc. (PRME) has 14 insiders with recent SEC Form 4 filings, including 8 buys and 0 sells. PRME is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 20.24M | $64.97M | - | |
| 10% | 6.23M | $20.00M | - | |
| 10% | 6.23M | $20.00M | - | |
| 10% | 6.23M | $20.00M | - | |
| Other | 181.0K | $581.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2024 | Nelsen Robert | Director, 10% Owner | Buy | 3,200,000 | $6.25 | $20,000,000.00 | New | -13.3% | -63.6% | |
| Feb 15, 2024 | Arch Venture Partners Xii, LLC63 | 10% Owner | Buy | 3,200,000 | $6.25 | $20,000,000.00 | New | -13.3% | -63.6% | |
| Feb 15, 2024 | Arch Venture Partners X, LLC | 10% Owner | Buy | 3,200,000 | $6.25 | $20,000,000.00 | New | -13.3% | -63.6% | |
| Oct 24, 2022 | Cahill Thomas | Director | Buy | 400,000 | $17.00 | $6,800,000.00 | +8.2% | +10.1% | -54.9% | |
| Oct 24, 2022 | Arch Venture Partners X, LLC | 10% Owner | Buy | 800,000 | $17.00 | $13,600,000.00 | +7.0% | +10.1% | -54.9% | |
| Oct 24, 2022 | Nelsen Robert | Director, 10% Owner | Buy | 800,000 | $17.00 | $13,600,000.00 | +7.0% | +10.1% | -54.9% |